

Christophe Schneider

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6160266/publications.pdf>

Version: 2024-02-01

26
papers

713
citations

623734

14
h-index

552781

26
g-index

26
all docs

26
docs citations

26
times ranked

1196
citing authors

#	ARTICLE	IF	CITATIONS
1	Discoidin Domain Receptor 1 Expression in Colon Cancer: Roles and Prognosis Impact. <i>Cancers</i> , 2022, 14, 928.	3.7	7
2	Adverse Effects of Oseltamivir Phosphate Therapy on the Liver of LDLR ^{-/-} Mice Without Any Benefit on Atherosclerosis and Thrombosis. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 77, 660-672.	1.9	6
3	Anti-Tumoral and Anti-Angiogenic Effects of Low-Diluted Phenacetinum on Melanoma. <i>Frontiers in Oncology</i> , 2021, 11, 597503.	2.8	4
4	LRP-1 Matricellular Receptor Involvement in Triple Negative Breast Cancer Tumor Angiogenesis. <i>Biomedicines</i> , 2021, 9, 1430.	3.2	7
5	Role of Endocytosis Proteins in Gefitinib-Mediated EGFR Internalisation in Glioma Cells. <i>Cells</i> , 2021, 10, 3258.	4.1	3
6	Contribution of the Low-Density Lipoprotein Receptor Family to Breast Cancer Progression. <i>Frontiers in Oncology</i> , 2020, 10, 882.	2.8	17
7	Low-diluted Phenacetinum disrupted the melanoma cancer cell migration. <i>Scientific Reports</i> , 2019, 9, 9109.	3.3	4
8	LRP1 expression in colon cancer predicts clinical outcome. <i>Oncotarget</i> , 2018, 9, 8849-8869.	1.8	28
9	Matricellular TSP-1 as a target of interest for impeding melanoma spreading: towards a therapeutic use for TAX2 peptide. <i>Clinical and Experimental Metastasis</i> , 2016, 33, 637-649.	3.3	16
10	Analysis of the effect of LRP-1 silencing on the invasive potential of cancer cells by nanomechanical probing and adhesion force measurements using atomic force microscopy. <i>Nanoscale</i> , 2016, 8, 7144-7154.	5.6	19
11	Biobanking of Fresh-Frozen Human Adenocarcinomatous and Normal Colon Tissues: Which Parameters Influence RNA Quality?. <i>PLoS ONE</i> , 2016, 11, e0154326.	2.5	17
12	Original insights on thrombospondin-1-related antireceptor strategies in cancer. <i>Frontiers in Pharmacology</i> , 2015, 6, 252.	3.5	86
13	Identification of TAX2 peptide as a new unpredicted anti-cancer agent. <i>Oncotarget</i> , 2015, 6, 17981-18000.	1.8	18
14	Low-Density Lipoprotein Receptor-Related Protein-1 Mediates Endocytic Clearance of Tissue Inhibitor of Metalloproteinases-1 and Promotes Its Cytokine-Like Activities. <i>PLoS ONE</i> , 2014, 9, e103839.	2.5	35
15	LRP-1 ^{CD44} , a New Cell Surface Complex Regulating Tumor Cell Adhesion. <i>Molecular and Cellular Biology</i> , 2012, 32, 3293-3307.	2.3	40
16	CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest. <i>British Journal of Pharmacology</i> , 2012, 167, 1415-1430.	5.4	135
17	LRP-1 Promotes Cancer Cell Invasion by Supporting ERK and Inhibiting JNK Signaling Pathways. <i>PLoS ONE</i> , 2010, 5, e11584.	2.5	76
18	De novo ceramide synthesis is responsible for the anti-tumor properties of camptothecin and doxorubicin in follicular thyroid carcinoma. <i>International Journal of Biochemistry and Cell Biology</i> , 2009, 41, 1165-1172.	2.8	48

#	ARTICLE	IF	CITATIONS
19	Interleukin-1 $\hat{1}$ ² -induced apoptosis through adenylyl cyclase and ERK1/2 inhibition in primary cultured thyroid cells. <i>Biochemical and Biophysical Research Communications</i> , 2006, 339, 469-476.	2.1	12
20	Thrombospondin-1 C-terminal-derived peptide protects thyroid cells from ceramide-induced apoptosis through the adenylyl cyclase pathway. <i>International Journal of Biochemistry and Cell Biology</i> , 2006, 38, 2219-2228.	2.8	26
21	The C-terminal CD47/IAP-binding domain of thrombospondin-1 prevents camptothecin- and doxorubicin-induced apoptosis in human thyroid carcinoma cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2006, 1763, 1125-1134.	4.1	56
22	Interleukin-1 $\hat{1}$ ² (IL-1 $\hat{1}$ ²) induces a crosstalk between cAMP and ceramide signaling pathways in thyroid epithelial cells. <i>Biochimie</i> , 2005, 87, 1121-1126.	2.6	4
23	TGFbeta1 effects on functional activity of porcine thyroid cells cultured in suspension. <i>Journal of Endocrinology</i> , 2002, 173, 345-355.	2.6	10
24	INTERLEUKIN 1 $\hat{1}$ ² (IL-1 $\hat{1}$ ²) ACTION IN PORCINE THYROID CELLS INVOLVES THE CERAMIDE SIGNALLING PATHWAY. <i>Cytokine</i> , 2001, 13, 174-178.	3.2	11
25	Involvement of the ceramide signaling pathway in modulating the differentiated state of porcine thyroid cells. <i>Lipids</i> , 2000, 35, 1259-1268.	1.7	6
26	Involvement of the 92-kDa Gelatinase (Matrix Metalloproteinase-9) in the Ceramide-Mediated Inhibition of Human Keratinocyte Growth. <i>Biochemical and Biophysical Research Communications</i> , 1999, 260, 634-640.	2.1	22